Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT07365696
Recruiting Observational

Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain.

NCT07365696 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska University Hospital
Phase
Observational
Started
2023-11-28
Last updated
2026-01-26

Condition(s) studied

FatigueGraft Vs Host DiseaseCognitive Dysfunction

Investigational drug(s) / intervention(s)

PET investigation

PET investigation: Trial subjects will undergo two advanced PET investigations

Study summary

Patients undergoing allogenic stem cell transplantation are regularly followed up in the outpatient clinic at Karolinska University Hospital. Here, patients are offered participation the fatigue study measuring both fatigue and cognitive impairment systematically by international standard. Meanwhile liquor samples and advanced PET imaging techniques are available for these patients as part of a research project allowing extensive immunological and radio-morphological studies.

Eligibility

Sex
ALL
Min age
20 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: PET images available retrospectively

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ksenia Boriskina Stockholm Sweden Recruiting

More Karolinska University Hospital trials in Sweden

Ablation of Fibrotic Areas in Patients With Persistent Atrial Fibrillation. Active, not recruiting
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases Recruiting
Timing of Renal Replacement Therapy in the Critically Ill Patients Recruiting
TENS for Relief of Postoperative Pain in Orthopedic Patients Active, not recruiting
Follow-up of Cell Changes in the Cervix Active, not recruiting

Other trials for the same condition

Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm Recruiting
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Active, not recruiting
Characterization, Treatment, and Long-term Follow-up of Fatigued Patients in Primary Care Recruiting
Fatigue and Cognitive Dysfunction After Allogeneic Stemcell Transplantation, Prospective PET Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07365696 on ClinicalTrials.gov ↗ ← All trials in Sweden